The emerging target KRAS G12C in genitourinary malignancies

被引：0
|
作者：
Grivas, Petros
Necchi, Andrea
Bratslavsky, Gennady
Shapiro, Oleg
Jacob, Joseph
Elvin, Julia Andrea
Vergilio, Jo-Anne
Killian, Keith
Williams, Erik
Ramkissoon, Shakti H.
Severson, Eric Allan
Hemmerich, Amanda
Schrock, Alexa Betzig
Chung, Jon
McGregor, Kimberly
Reddy, Prasanth
Alexander, Brian Michael
Sokol, Ethan
Danziger, Natalie
Ross, Jeffrey S.
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[5] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
434
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Covalent Guanosine Mimetic Inhibitors of G12C KRAS
    Xiong, Yuan
    Lu, Jia
    Hunter, John
    Li, Lianbo
    Scott, David
    Choi, Hwan Geun
    Lim, Sang Min
    Manandhar, Anuj
    Gondi, Sudershan
    Sim, Taebo
    Westover, Kenneth D.
    Gray, Nathanael S.
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (01): : 61 - 66
  • [22] Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
    Woodcock, M.
    Tsai, Y. S.
    Azam, S. H.
    Thorne, L. B.
    Kanchi, K. L.
    Parker, J. S.
    Vincent, B. G.
    Pecot, C. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S599 - S600
  • [23] Targeting KRAS G12C mutation in lung adenocarcinoma
    Rohatgi, Anjali
    Govindan, Ramaswamy
    LUNG CANCER, 2022, 165 : 28 - 33
  • [24] Targeting KRAS G12C mutations in colorectal cancer
    Zhao, Ming-He
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [25] KRAS G12C inhibition and innate immune targeting
    Tani, Tetsuo
    Kitajima, Shunsuke
    Conway, Ella B.
    Knelson, Erik H.
    Barbie, David A.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (03) : 167 - 174
  • [26] Overcoming adaptive resistance to KRAS G12C inhibitors
    Adachi, Yuta
    Niitsu, Hiroaki
    Yamaguchi, Rui
    Ebi, Hiromichi
    CANCER SCIENCE, 2024, 115 : 110 - 110
  • [27] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
    Pinto, L. Masfarre
    Rocha, P.
    Clave, S.
    Gorro, N. Navarro
    Sanchez, I.
    Giner, M.
    Lloret, A. Corbera
    Garcia, A. Taus
    Parreira, A. S. D. F. M.
    Paricio, B. Bellosillo
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
  • [28] The Emerging Role of KRAS G12C Inhibitors in the Treatment of Locally Advanced or Metastatic Colorectal Cancer
    Ciombor, Kristen
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (08) : 503 - 505
  • [29] Sotorasib-modified KRAS G12C MHC I complex as a target for cancer theranostics
    Pandey, Apurva
    Rohweder, Peter
    Chan, Lieza
    Ongpipattanakul, Chayanid
    Paolella, Bryce
    Quimby, Fiona
    Verba, Kliment
    Evans, Michael
    Craik, Charles
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [30] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
12345